These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24440965)

  • 21. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.
    Claret L; Lu JF; Sun YN; Bruno R
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1141-9. PubMed ID: 20872147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.
    Sawaki A; Yamada Y; Komatsu Y; Kanda T; Doi T; Koseki M; Baba H; Sun YN; Murakami K; Nishida T
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):961-7. PubMed ID: 19690858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases.
    Kawaguchi T; Matsumura A; Fukai S; Tamura A; Saito R; Zell JA; Maruyama Y; Ziogas A; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 Jul; 5(7):1001-10. PubMed ID: 20526205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.
    Ou SH; Ziogas A; Zell JA
    J Thorac Oncol; 2009 Sep; 4(9):1083-93. PubMed ID: 19652625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
    Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
    Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.
    Ahn MJ; Lee J; Park YH; Ahn JS; Ziogas A; Zell JA; Park K; Ou SH
    J Thorac Oncol; 2010 Aug; 5(8):1185-96. PubMed ID: 20592628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.
    Zhang JW; Zhao YY; Guo Y; Xue C; Hu ZH; Huang Y; Zhao HY; Zhang J; Wu X; Fang WF; Ma YX; Zhang L
    Chin J Cancer; 2014 Feb; 33(2):105-14. PubMed ID: 23816558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
    Hasegawa Y; Kawaguchi T; Kubo A; Ando M; Shiraishi J; Isa S; Tsuji T; Tsujino K; Ou SH; Nakagawa K; Takada M
    J Thorac Oncol; 2011 Nov; 6(11):1881-8. PubMed ID: 21841503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials.
    Soo RA; Loh M; Mok TS; Ou SH; Cho BC; Yeo WL; Tenen DG; Soong R
    J Thorac Oncol; 2011 Jun; 6(6):1030-8. PubMed ID: 21532500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
    Wu YL; Kim JH; Park K; Zaatar A; Klingelschmitt G; Ng C
    Lung Cancer; 2012 Aug; 77(2):339-45. PubMed ID: 22494567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial.
    Lee DH; Lee JS; Wang J; Hsia TC; Wang X; Kim J; Orlando M
    Cancer Res Treat; 2015 Oct; 47(4):616-29. PubMed ID: 25672577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
    Bass MB; Sherman SI; Schlumberger MJ; Davis MT; Kivman L; Khoo HM; Notari KH; Peach M; Hei YJ; Patterson SD
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5018-27. PubMed ID: 20739388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.
    Gosselin NH; Mouksassi MS; Lu JF; Hsu CP
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):463-72. PubMed ID: 27137719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
    Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang S; Mao XD; Wang HT; Cai F; Xu J
    BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.